Assessing the performance of the Birmingham vasculitis activity score at diagnosis for Children with antineutrophil cytoplasmic antibody-associated vasculitis in a registry for childhood vasculitis (ARChiVe)

Kimberly Morishita, Suzanne C. Li, Eyal Muscal, Steven Spalding, Jaime Guzman, America Uribe, Leslie Abramson, Kevin Baszis, Susanne Benseler, Suzanne Bowyer, Sarah Campillo, Peter Chira, Aimee O. Hersh, Gloria Higgins, Anne Eberhard, Kaleo Ede, Lisa Imundo, Lawrence Jung, Susan Kim, Daniel J. Kingsbury & 16 others Marisa Klein-Gitelman, Erica F. Lawson, Daniel J. Lovell, Thomas Mason, Deborah McCurdy, Kabita Nanda, Lorien Nassi, Kathleen M. O'Neil, Egla Rabinovich, Suzanne E. Ramsey, Andreas Reiff, Margalit Rosenkranz, Kenneth Schikler, Anne Stevens, Dawn Wahezi, David A. Cabral

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: There are no validated tools for measuring disease activity in pediatric vasculitis. The Birmingham Vasculitis Activity Score (BVAS) is a valid disease activity tool in adult vasculitis. Version 3 (BVAS v.3) correlates well with physician's global assessment (PGA), treatment decision, and C-reactive protein in adults. The utility of BVAS v.3 in pediatric vasculitis is not known. We assessed the association of BVAS v.3 scores with PGA, treatment decision, and erythrocyte sedimentation rate (ESR) at diagnosis in pediatric antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Methods: Children with AAV diagnosed between 2004 and 2010 at all ARChiVe centers were eligible. BVAS v.3 scores were calculated with a standardized online tool (www.vasculitis.org). Spearman's rank correlation coefficient (rs) was used to test the strength of association between BVAS v.3 and PGA, treatment decision, and ESR. Results: A total of 152 patients were included. The physician diagnosis of these patients was predominantly granulomatosis with polyangiitis (n = 99). The median BVAS v.3 score was 18.0 (range 0-40). The BVAS v.3 correlations were rs = 0.379 (95% CI 0.233 to 0.509) with PGA, rs = 0.521 (95% CI 0.393 to 0.629) with treatment decision, and rs = 0.403 (95% CI 0.253 to 0.533) with ESR. Conclusion: Applied to children with AAV, BVAS v.3 had a weak correlation with PGA and moderate correlation with both ESR and treatment decision. Prospective evaluation of BVAS v.3 and/or pediatric-specific modifications to BVAS v.3 may be required before it can be formalized as a disease activity assessment tool in pediatric AAV.

Original languageEnglish (US)
Pages (from-to)1088-1094
Number of pages7
JournalJournal of Rheumatology
Volume39
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Antineutrophil Cytoplasmic Antibodies
Vasculitis
Registries
Blood Sedimentation
Physicians
Pediatrics
Antibodies
Therapeutics
Granulomatosis with Polyangiitis

Keywords

  • Anca
  • Antineutrophil cytoplasmic antibodies
  • Vasculitis
  • Wegener granulomatosis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Assessing the performance of the Birmingham vasculitis activity score at diagnosis for Children with antineutrophil cytoplasmic antibody-associated vasculitis in a registry for childhood vasculitis (ARChiVe). / Morishita, Kimberly; Li, Suzanne C.; Muscal, Eyal; Spalding, Steven; Guzman, Jaime; Uribe, America; Abramson, Leslie; Baszis, Kevin; Benseler, Susanne; Bowyer, Suzanne; Campillo, Sarah; Chira, Peter; Hersh, Aimee O.; Higgins, Gloria; Eberhard, Anne; Ede, Kaleo; Imundo, Lisa; Jung, Lawrence; Kim, Susan; Kingsbury, Daniel J.; Klein-Gitelman, Marisa; Lawson, Erica F.; Lovell, Daniel J.; Mason, Thomas; McCurdy, Deborah; Nanda, Kabita; Nassi, Lorien; O'Neil, Kathleen M.; Rabinovich, Egla; Ramsey, Suzanne E.; Reiff, Andreas; Rosenkranz, Margalit; Schikler, Kenneth; Stevens, Anne; Wahezi, Dawn; Cabral, David A.

In: Journal of Rheumatology, Vol. 39, No. 5, 05.2012, p. 1088-1094.

Research output: Contribution to journalArticle

Morishita, K, Li, SC, Muscal, E, Spalding, S, Guzman, J, Uribe, A, Abramson, L, Baszis, K, Benseler, S, Bowyer, S, Campillo, S, Chira, P, Hersh, AO, Higgins, G, Eberhard, A, Ede, K, Imundo, L, Jung, L, Kim, S, Kingsbury, DJ, Klein-Gitelman, M, Lawson, EF, Lovell, DJ, Mason, T, McCurdy, D, Nanda, K, Nassi, L, O'Neil, KM, Rabinovich, E, Ramsey, SE, Reiff, A, Rosenkranz, M, Schikler, K, Stevens, A, Wahezi, D & Cabral, DA 2012, 'Assessing the performance of the Birmingham vasculitis activity score at diagnosis for Children with antineutrophil cytoplasmic antibody-associated vasculitis in a registry for childhood vasculitis (ARChiVe)', Journal of Rheumatology, vol. 39, no. 5, pp. 1088-1094. https://doi.org/10.3899/jrheum.111030
Morishita, Kimberly ; Li, Suzanne C. ; Muscal, Eyal ; Spalding, Steven ; Guzman, Jaime ; Uribe, America ; Abramson, Leslie ; Baszis, Kevin ; Benseler, Susanne ; Bowyer, Suzanne ; Campillo, Sarah ; Chira, Peter ; Hersh, Aimee O. ; Higgins, Gloria ; Eberhard, Anne ; Ede, Kaleo ; Imundo, Lisa ; Jung, Lawrence ; Kim, Susan ; Kingsbury, Daniel J. ; Klein-Gitelman, Marisa ; Lawson, Erica F. ; Lovell, Daniel J. ; Mason, Thomas ; McCurdy, Deborah ; Nanda, Kabita ; Nassi, Lorien ; O'Neil, Kathleen M. ; Rabinovich, Egla ; Ramsey, Suzanne E. ; Reiff, Andreas ; Rosenkranz, Margalit ; Schikler, Kenneth ; Stevens, Anne ; Wahezi, Dawn ; Cabral, David A. / Assessing the performance of the Birmingham vasculitis activity score at diagnosis for Children with antineutrophil cytoplasmic antibody-associated vasculitis in a registry for childhood vasculitis (ARChiVe). In: Journal of Rheumatology. 2012 ; Vol. 39, No. 5. pp. 1088-1094.
@article{fd18e1d849b147df8f7c21a0885b38a2,
title = "Assessing the performance of the Birmingham vasculitis activity score at diagnosis for Children with antineutrophil cytoplasmic antibody-associated vasculitis in a registry for childhood vasculitis (ARChiVe)",
abstract = "Objective: There are no validated tools for measuring disease activity in pediatric vasculitis. The Birmingham Vasculitis Activity Score (BVAS) is a valid disease activity tool in adult vasculitis. Version 3 (BVAS v.3) correlates well with physician's global assessment (PGA), treatment decision, and C-reactive protein in adults. The utility of BVAS v.3 in pediatric vasculitis is not known. We assessed the association of BVAS v.3 scores with PGA, treatment decision, and erythrocyte sedimentation rate (ESR) at diagnosis in pediatric antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Methods: Children with AAV diagnosed between 2004 and 2010 at all ARChiVe centers were eligible. BVAS v.3 scores were calculated with a standardized online tool (www.vasculitis.org). Spearman's rank correlation coefficient (rs) was used to test the strength of association between BVAS v.3 and PGA, treatment decision, and ESR. Results: A total of 152 patients were included. The physician diagnosis of these patients was predominantly granulomatosis with polyangiitis (n = 99). The median BVAS v.3 score was 18.0 (range 0-40). The BVAS v.3 correlations were rs = 0.379 (95{\%} CI 0.233 to 0.509) with PGA, rs = 0.521 (95{\%} CI 0.393 to 0.629) with treatment decision, and rs = 0.403 (95{\%} CI 0.253 to 0.533) with ESR. Conclusion: Applied to children with AAV, BVAS v.3 had a weak correlation with PGA and moderate correlation with both ESR and treatment decision. Prospective evaluation of BVAS v.3 and/or pediatric-specific modifications to BVAS v.3 may be required before it can be formalized as a disease activity assessment tool in pediatric AAV.",
keywords = "Anca, Antineutrophil cytoplasmic antibodies, Vasculitis, Wegener granulomatosis",
author = "Kimberly Morishita and Li, {Suzanne C.} and Eyal Muscal and Steven Spalding and Jaime Guzman and America Uribe and Leslie Abramson and Kevin Baszis and Susanne Benseler and Suzanne Bowyer and Sarah Campillo and Peter Chira and Hersh, {Aimee O.} and Gloria Higgins and Anne Eberhard and Kaleo Ede and Lisa Imundo and Lawrence Jung and Susan Kim and Kingsbury, {Daniel J.} and Marisa Klein-Gitelman and Lawson, {Erica F.} and Lovell, {Daniel J.} and Thomas Mason and Deborah McCurdy and Kabita Nanda and Lorien Nassi and O'Neil, {Kathleen M.} and Egla Rabinovich and Ramsey, {Suzanne E.} and Andreas Reiff and Margalit Rosenkranz and Kenneth Schikler and Anne Stevens and Dawn Wahezi and Cabral, {David A.}",
year = "2012",
month = "5",
doi = "10.3899/jrheum.111030",
language = "English (US)",
volume = "39",
pages = "1088--1094",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "5",

}

TY - JOUR

T1 - Assessing the performance of the Birmingham vasculitis activity score at diagnosis for Children with antineutrophil cytoplasmic antibody-associated vasculitis in a registry for childhood vasculitis (ARChiVe)

AU - Morishita, Kimberly

AU - Li, Suzanne C.

AU - Muscal, Eyal

AU - Spalding, Steven

AU - Guzman, Jaime

AU - Uribe, America

AU - Abramson, Leslie

AU - Baszis, Kevin

AU - Benseler, Susanne

AU - Bowyer, Suzanne

AU - Campillo, Sarah

AU - Chira, Peter

AU - Hersh, Aimee O.

AU - Higgins, Gloria

AU - Eberhard, Anne

AU - Ede, Kaleo

AU - Imundo, Lisa

AU - Jung, Lawrence

AU - Kim, Susan

AU - Kingsbury, Daniel J.

AU - Klein-Gitelman, Marisa

AU - Lawson, Erica F.

AU - Lovell, Daniel J.

AU - Mason, Thomas

AU - McCurdy, Deborah

AU - Nanda, Kabita

AU - Nassi, Lorien

AU - O'Neil, Kathleen M.

AU - Rabinovich, Egla

AU - Ramsey, Suzanne E.

AU - Reiff, Andreas

AU - Rosenkranz, Margalit

AU - Schikler, Kenneth

AU - Stevens, Anne

AU - Wahezi, Dawn

AU - Cabral, David A.

PY - 2012/5

Y1 - 2012/5

N2 - Objective: There are no validated tools for measuring disease activity in pediatric vasculitis. The Birmingham Vasculitis Activity Score (BVAS) is a valid disease activity tool in adult vasculitis. Version 3 (BVAS v.3) correlates well with physician's global assessment (PGA), treatment decision, and C-reactive protein in adults. The utility of BVAS v.3 in pediatric vasculitis is not known. We assessed the association of BVAS v.3 scores with PGA, treatment decision, and erythrocyte sedimentation rate (ESR) at diagnosis in pediatric antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Methods: Children with AAV diagnosed between 2004 and 2010 at all ARChiVe centers were eligible. BVAS v.3 scores were calculated with a standardized online tool (www.vasculitis.org). Spearman's rank correlation coefficient (rs) was used to test the strength of association between BVAS v.3 and PGA, treatment decision, and ESR. Results: A total of 152 patients were included. The physician diagnosis of these patients was predominantly granulomatosis with polyangiitis (n = 99). The median BVAS v.3 score was 18.0 (range 0-40). The BVAS v.3 correlations were rs = 0.379 (95% CI 0.233 to 0.509) with PGA, rs = 0.521 (95% CI 0.393 to 0.629) with treatment decision, and rs = 0.403 (95% CI 0.253 to 0.533) with ESR. Conclusion: Applied to children with AAV, BVAS v.3 had a weak correlation with PGA and moderate correlation with both ESR and treatment decision. Prospective evaluation of BVAS v.3 and/or pediatric-specific modifications to BVAS v.3 may be required before it can be formalized as a disease activity assessment tool in pediatric AAV.

AB - Objective: There are no validated tools for measuring disease activity in pediatric vasculitis. The Birmingham Vasculitis Activity Score (BVAS) is a valid disease activity tool in adult vasculitis. Version 3 (BVAS v.3) correlates well with physician's global assessment (PGA), treatment decision, and C-reactive protein in adults. The utility of BVAS v.3 in pediatric vasculitis is not known. We assessed the association of BVAS v.3 scores with PGA, treatment decision, and erythrocyte sedimentation rate (ESR) at diagnosis in pediatric antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Methods: Children with AAV diagnosed between 2004 and 2010 at all ARChiVe centers were eligible. BVAS v.3 scores were calculated with a standardized online tool (www.vasculitis.org). Spearman's rank correlation coefficient (rs) was used to test the strength of association between BVAS v.3 and PGA, treatment decision, and ESR. Results: A total of 152 patients were included. The physician diagnosis of these patients was predominantly granulomatosis with polyangiitis (n = 99). The median BVAS v.3 score was 18.0 (range 0-40). The BVAS v.3 correlations were rs = 0.379 (95% CI 0.233 to 0.509) with PGA, rs = 0.521 (95% CI 0.393 to 0.629) with treatment decision, and rs = 0.403 (95% CI 0.253 to 0.533) with ESR. Conclusion: Applied to children with AAV, BVAS v.3 had a weak correlation with PGA and moderate correlation with both ESR and treatment decision. Prospective evaluation of BVAS v.3 and/or pediatric-specific modifications to BVAS v.3 may be required before it can be formalized as a disease activity assessment tool in pediatric AAV.

KW - Anca

KW - Antineutrophil cytoplasmic antibodies

KW - Vasculitis

KW - Wegener granulomatosis

UR - http://www.scopus.com/inward/record.url?scp=84860781239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860781239&partnerID=8YFLogxK

U2 - 10.3899/jrheum.111030

DO - 10.3899/jrheum.111030

M3 - Article

VL - 39

SP - 1088

EP - 1094

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 5

ER -